Vittorini Simona, Clerico Aldo
Institute of Clinical Physiology - National Research Council, Pisa, Italy.
Clin Chem Lab Med. 2008;46(6):748-63. doi: 10.1515/CCLM.2008.188.
The practice of cardiology is in continual evolution, in parallel with the progress achieved by medical research in understanding the pathophysiology of cardiovascular disease and in developing new therapeutic procedures. Consequently, manufacturers of cardiac biomarkers are pressed with new demands to improve the performance of the existing and the development of novel ones. Several highly sensitive and/or specific assays for myocardial ischemic damage and myocardial function detection have already become commercially available. Moreover, an increasing number of novel risk factors have been added to the classical risk factors of cardiovascular disease. Finally, the recent surge of genetic analysis procedures will likely soon provide the clinical cardiologist with a number of laboratory tests for defining the molecular diagnosis, assessing new risk factors, and better targeting the pharmaceutical approaches in patients with cardiovascular disease. In this review, we first present the general characteristics of a biomarker followed by the analytical and clinical performance of assay methods.
心脏病学实践处于不断发展之中，这与医学研究在理解心血管疾病病理生理学以及开发新治疗方法方面所取得的进展同步。因此，心脏生物标志物制造商面临新的要求，即提高现有产品的性能并开发新型产品。几种用于检测心肌缺血损伤和心肌功能的高灵敏度和/或特异性检测方法已上市。此外，越来越多的新型危险因素已被纳入心血管疾病的经典危险因素中。最后，近期基因分析方法的激增可能很快会为临床心脏病学家提供一系列实验室检测，用于确定分子诊断、评估新的危险因素以及更精准地针对心血管疾病患者进行药物治疗。在本综述中，我们首先介绍生物标志物的一般特征，然后阐述检测方法的分析性能和临床性能。
